VISEN Pharmaceuticals announced that on 19 May 2026 it repurchased 6,200 ordinary shares on the Hong Kong Stock Exchange. The transaction represents 0.005 % of the company’s issued share capital (excluding treasury shares) prior to the buyback.

The shares were acquired at prices ranging from HKD 23.00 to HKD 24.56, for a total consideration of HKD 0.15 million. All repurchased shares are being held as treasury stock.

Following the transaction, VISEN Pharma’s issued shares outstanding (excluding treasury shares) decreased to 113.91 million, while total issued shares remained at 113.93 million. The company’s treasury stock position increased from 9,200 to 15,400 shares.

The repurchase falls under a mandate approved on 27 June 2025 that allows VISEN Pharma to buy back up to 11.39 million shares. To date, 15,400 shares, or 0.01352 % of the share count at the mandate date, have been repurchased under this authorization.

Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 18 June 2026.